¼¼°èÀÇ Àª½¼º´ Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°, Åõ¿© °æ·Îº°, ¿¬·ÉÃþº°, À¯Åë ä³Îº°, Áö¿ªº°
Wilson¢¥s Disease Treatment Market, By Type of Treatment, By Route of Administration, By Age Group, By Distribution Channel, By Geography
»óǰÄÚµå : 1671893
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,385,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,933,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,191,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Àª½¼º´ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2025³â¿¡´Â 6¾ï 3,080¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 9¾ï 9,320¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2032³â ¿¬Æò±Õ 6.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ´ë»ó ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 6¾ï 3,080¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR: 6.70% 2032³â °¡Ä¡ ¿¹Ãø 9¾ï 9,320¸¸ ´Þ·¯
Àª½¼º´ Ä¡·á ½ÃÀå Á¡À¯À²(%), 2025³â, Áö¿ªº°
Wilson's Disease Treatment Market-IMG1

Àª½¼º´Àº °£À̳ª ³ú¿Í °°Àº ´Ù¸¥ Áß¿äÇÑ Àå±â¿¡ ±¸¸®°¡ ÃàÀûµÇ´Â Èñ±ÍÇÑ À¯Àü ÁúȯÀÔ´Ï´Ù. ´ãÁó°ú ¼Òº¯À» ÅëÇØ ±¸¸®¸¦ ¹èÃâÇÏ´Â ½ÅüÀÇ ´É·Â¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. Àª½¼º´À» Ä¡·áÇÏÁö ¾Ê°í ¹æÄ¡ÇÏ¸é ½É°¢ÇÑ ÀÇÇÐÀû ¹®Á¦¸¦ ÀÏÀ¸Å°°í »ç¸Á¿¡ ´ÞÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ±×·¯³ª ÀûÀýÇÑ Áø´Ü°ú Ä¡·á¸¦ ÅëÇØ ȯÀÚÀÇ ±â´ë ¼ö¸íÀ» Å©°Ô Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ÀÌ Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´õ ¸¹Àº ȯÀÚµéÀÌ Áø´ÜÀ» ¹Þ°í È¿°úÀûÀÎ Ä¡·á¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ¿¹Ãø ±â°£ Áß ¼¼°è Àª½¼º´ Ä¡·á ½ÃÀåÀÇ ²ÙÁØÇÑ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è Àª½¼º´ Ä¡·á ½ÃÀåÀº Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä °³¼±°ú »õ·Î¿î Áø´Ü¹ýÀ¸·Î ÀÎÇØ ¿Ï¸¸ÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ½Å±Ô Ä¡·áÁ¦ °³¹ßµµ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ±×·¯³ª ±¸¸® ų·¹ÀÌÆ®Á¦´Â Èñ±ÍÁúȯ Ä¡·áÁ¦À̱⠶§¹®¿¡ ºñ¿ëÀÌ ³ô¾Æ ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ °³¹ßµµ»ó±¹¿¡¼­´Â Áúº´¿¡ ´ëÇÑ ÀνÄÀÌ ³·´Ù´Â Á¡µµ ¹®Á¦ÀÔ´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí ÀÚ¹ßÀû ´Üü¿Í Á¤ºÎ Áö¿ø ÇÁ·Î±×·¥À» ÅëÇÑ ±¸»óÀº ƯÈ÷ ÁßÀú¼Òµæ ±¹°¡¿¡¼­ ±¸¸Å ¿ëÀ̼º ¹®Á¦¸¦ ÇØ°áÇϰí Áø´ÜÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ Àª½¼º´ Ä¡·á ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è Àª½¼º´ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ °³¿äÀ» ±â¾÷ °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ ±âÁØÀ¸·Î Á¤¸®ÇÏ¿© ¼ö·ÏÇÏ¿´½À´Ï´Ù.

º» Á¶»çÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷¿¡´ÂValeant Pharmaceuticals International, Merck & Co, Tsumura & Co, VHB Life Science Inc., Teva Pharmaceuticals USA Inc., Wilson's Therapeutics AB, Noble Pharma Co. Ltd, Kadmon Holdings Inc., Zydus Cadila, Mylan N.V., Hikma Pharmaceuticals, Sandoz (a Novartis division), Aurobindo Pharma, Amgen Inc., Pfizer Inc. µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¸¦ ÅëÇØ ¾òÀº ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è Àª½¼º´ Ä¡·á ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è Àª½¼º´ Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ Àª½¼º´ Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°(2020-2032³â)

Á¦5Àå ¼¼°èÀÇ Àª½¼º´ Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°(2020-2032³â)

Á¦6Àå ¼¼°èÀÇ Àª½¼º´ Ä¡·á ½ÃÀå : ¿¬·ÉÃþº°(2020-2032³â)

Á¦7Àå ¼¼°èÀÇ Àª½¼º´ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°(2020-2032³â)

Á¦8Àå ¼¼°èÀÇ Àª½¼º´ Ä¡·á ½ÃÀå : Áö¿ªº°(2020-2032³â)

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

Á¦11Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Wilson's Disease Treatment Market is estimated to be valued at US$ 630.8 Mn in 2025 and is expected to reach US$ 993.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: US$ 630.8 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.70% 2032 Value Projection: US$ 993.2 Mn
Wilson's Disease Treatment Market Share (%), By Region 2025
Wilson's Disease Treatment Market - IMG1

Wilson's disease is a rare genetic disorder that causes copper to accumulate in the liver and other vital organs like the brain. It affects the ability of the body to release copper through bile and urine. Untreated Wilson's disease can cause serious medical problems and may become fatal. However, with proper diagnosis and treatment, life expectancy of patients can be improved significantly. As awareness about this condition is rising globally, more patients are being diagnosed and treated effectively. This is expected to drive steady growth in the global Wilson's disease treatment market during the forecast period.

Market Dynamics:

The global Wilson's disease treatment market is anticipated to witness moderate growth attributed to rising disease awareness and new diagnosis. Development of novel drugs for treatment is also expected to provide opportunities. However, high costs associated with copper-chelating agents, being orphan drugs, can hamper market expansion to some extent. Additionally, lack of disease awareness in developing nations poses a challenge. Nonetheless, initiatives by voluntary organizations as well as government support programs can help address affordability issues and improve diagnosis especially in low-and middle-income countries.

Key Features of the Study:

This report provides in-depth analysis of the global Wilson's disease treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global Wilson's disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Valeant Pharmaceuticals International, Merck & Co, Tsumura & Co, VHB Life Science Inc., Teva Pharmaceuticals USA Inc., Wilson's Therapeutics AB, Noble Pharma Co. Ltd, Kadmon Holdings Inc., Zydus Cadila, Mylan N.V., Hikma Pharmaceuticals, Sandoz (a Novartis division), Aurobindo Pharma, Amgen Inc., and Pfizer Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global Wilson's disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Wilson's disease treatment market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Wilson's Disease Treatment Market, By Type of Treatment, 2020-2032, (USD Mn)

5. Global Wilson's Disease Treatment Market, By Route of Administration, 2020-2032, (USD Mn)

6. Global Wilson's Disease Treatment Market, By Age Group, 2020-2032, (USD Mn)

7. Global Wilson's Disease Treatment Market, By Distribution Channel, 2020-2032, (USD Mn)

8. Global Wilson's Disease Treatment Market, By Region, 2020 - 2032, Value (USD Mn)

9. Competitive Landscape

10. Analyst Recommendations

11. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â